Zusammenfassung
Die Riesenzellarteriitis ist die häufigste Form der systemischen Vaskulitiden und betrifft große und mittelgroße Gefäße. Als Standard in der Therapie der Riesenzellarteriitis gelten die Glukokortikoide. Zusätzlich wird von der „European League Against Rheumatism“ (EULAR) eine steroideinsparende Therapie empfohlen. Anhand der Datenlage ist dabei Methotrexat zu favorisieren. Mögliche Alternativen stellen Azathioprin, Tumor-Nekrose-Faktor-α-Inhibitoren und Cyclophosphamid dar.
Abstract
Giant cell arteritis is the most common systemic vasculitis and affects large and medium-sized vessels. Glucocorticoids are the current standard in the therapy of giant cell arteritis. To reduce the glucocorticoid dose the European League Against Rheumatism (EULAR) suggests the addition of disease-modifying antirheumatic drugs. Of these, methotrexate represents the best investigated drug; possible alternatives include azathioprine, tumor necrosis factor-alpha inhibitors and cyclophosphamide.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Bhatia A, Ell PJ, Edwards JC et al (2005) Anti-CD20 mononclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64:1099–1100
Cantini F, Niccoli L, Salvarani C et al (2001) Treatment of longstanding active giant cell arteritis with infliximab. Report of four cases. Arthritis Rheum 44:2933–2935
Chevalet P, Barrier JH, Pottier P et al (2000) A randomized multicenter, controlled trial using intravenous pulses of methyprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol 27:1484–1491
De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Arthritis Rheum 45:136–138
De Vita S, Tavoni A, Jeracitano G et al (1992) Treatment of giant cell arteritis with cyclophosphamide pulses. J Interne Med 232:373–375
Field M, Cook A, Gallagher G (1997) Immuno-localisation of tumor necrosis factor and its receptors in temporal arteritis. Rheumatol Int 17:113–118
Hayreh SS, Zimmermann B (2003) Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 217:239–259
Hernandez–Rodrigues J, Segarra M, Vilardell C et al (2004) Tissue production of pro-inflammatory cytokines (IL-1ß, TNF-α and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant cell arteritis. Rheumatololy (Oxford) 43:294–301
Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630
Hoffmann GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318
Jover JA, Hernandez-Garcia C, Morado IC et al (2001) Combined treatment of giant cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106–114
Le Guennec P, Dromer C, Sixou L et al (1994) Treatment of Horton’s disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients. Rheum (Engl Ed) 61:485–490
Lee MS, Smith SD, Galor A et al (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54:3306–3309
Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis. Arthritis Rheum 56:2789–2797
Martínez-Taboada MV, Rodríguez-Valverde V, Carreño L et al (2008) A double-blind placebo-controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630
Mazlumzadeh M, Hunder GG, Easley KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54:3310–3318
Mubashir Ahmed M, Mubashir E, Hayat S et al (2007) Treatment of refractory temporal arteritis with adalimumab. Case report. Clin Rheumatol 26:1353–1355
Mukhtyar C, Guillevin L, Cid MC et al (2008) EULAR Recommendations for the management of large vessel vasculitis. Ann Rheum Dis [Epub ahead of print]
Nesher G, Berkun Y, Mates M et al (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50:1332–1337
Proven A, Gabriel SE, Orces C et al (2003) Glucocorticoid therapy in giant cell arthritis: duration and adverse outcomes. Arthritis Rheum 49:703–708
Roblet P (1998) Immunsuppressive agents in Horton’s disease. Which drugs for which indication? Ann Med Interne (Paris) 149:441–447
Salvarani C, Pipitone N, Boiardi L et al (2008) Do we need treatment with tumour necrosis factor blockers for giant cell arteritis? Ann Rheum Dis 67:577–579
Schaufelberger C, Mollby H, Uddhammar A et al (2006) No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35:327–329
Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA) Clin Exp Rheumatol 19:495–501
Weyand CM, Fulbright JW, Hunder GG et al (2000) Treatment of giant cell arteritis: interleukin-6 as a biological marker of disease activity. Arthritis Rheum 43:1041–1048
Interessenkonflikt
Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wipfler-Freißmuth, E., Loock, J., Moosig, F. et al. Aktuelle Therapieansätze bei Riesenzellarteriitis. Z. Rheumatol. 68, 132–136 (2009). https://doi.org/10.1007/s00393-008-0378-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-008-0378-2